SCHEMBL19209110

SCHEMBL19209110

CC(Br)=C(C=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
HTT P42858 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
PKM P14618 2/20 0.43
ATM Q13315 2/20 0.43
HPGD P15428 2/20 0.43
NLRP1 Q9C000 1/20 0.43
MEN1 O00255 1/20 0.43
NTSR1 P30989 1/20 0.43
KMT2A Q03164 1/20 0.43
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43
GSK3B P49841 1/20 0.41
GAA P10253 1/20 0.39
MAPT P10636 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19209109 1.00 ALDH1A1 (0.43) ALDH1A1HTTNPSR1LMNASMN1; SMN2
SCHEMBL19209092 0.81 ALDH1A1 (0.46) ALDH1A1LMNATDP1ATMMEN1
SCHEMBL19243244 0.81 ALDH1A1 (0.46) ALDH1A1LMNATDP1ATMMEN1
SCHEMBL19209090 0.81 ALDH1A1 (0.46) ALDH1A1LMNATDP1ATMMEN1
SCHEMBL19243167 0.72 ALDH1A1 (0.59) ALDH1A1HTTNPSR1LMNASMN1; SMN2
SCHEMBL20677758 0.72 ALDH1A1 (0.59) ALDH1A1HTTNPSR1LMNASMN1; SMN2
SCHEMBL1107500 0.69 ALDH1A1 (0.70) ALDH1A1HTTNPSR1LMNASMN1; SMN2
SCHEMBL20677705 0.68 POLB (0.51) ALDH1A1HTTLMNASMN1; SMN2PKM
SCHEMBL20677704 0.68 POLB (0.51) ALDH1A1HTTLMNASMN1; SMN2PKM
SCHEMBL6714893 0.68 ALDH1A1 (0.45) ALDH1A1HTTNPSR1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
EP-3400226-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER Emcure Pharmaceuticals Limited (IN) 2018-11-14 EP disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER IDO1, IDO2, TDO2 ALDH1A1 946/4885HTT 897/4885NPSR1 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.